MedTrace Logo

The Post-Marketing Safety and Immunogenicity Research of Speeda® Rabies Vaccine for Human Use

NCT01821911 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 10500

Last updated 2016-01-20

No results posted yet for this study

Summary

The objective of this study was to achieve the post-marketing safety and immunogenicity research of Speeda® rabies vaccine for human use from Chengda Bio

Conditions

  • Rabies Vaccine Allergy
  • Vaccination Adverse Event
  • Anti-D Antibodies

Interventions

BIOLOGICAL

Zagreb2-1-1

Injection on day 0、7、21

BIOLOGICAL

Essen

Injection on day 0、3、7、14、28

Sponsors & Collaborators

  • Beijing Center for Disease Control and Prevention

    lead OTHER_GOV

Principal Investigators

  • Nianmin Shi · Beijing Chaoyang District Centers for Disease Control and Prevention

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-07-31
Primary Completion
2013-12-31
Completion
2014-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01821911 on ClinicalTrials.gov